Abstract
Endometrial cancer is a highly curable malignancy when it presents as uterine-confined disease, but the prognosis for metastatic or recurrent endometrial cancer is poor. For those patients which are diagnosed at an early stage, surgery alone may be adequate for cure and clinical outcome is often favorable, with approximately 80 % of cases surviving at 5 years. However, after primary diagnosis and treatment, roughly 20-30% of patients are expected to recur within the following 5 years. Adjuvant treatment for endometrial cancer is not yet clearly defined. FIGO Stage I-III endometrial cancer patients, usually undergo surgery and some of them are offered adjuvant treatment based on risk assessment. Grade, age, stage are considered all independent risk factors for recurrence. Radiotherapy (RT) has been considered the adjuvant treatment of choice for decades, being able to reduce local recurrence rate and improving progression free survival, but without any impact on overall survival. In the last two decades, a shift toward the use of systemic chemotherapy (CT) in addition or instead of radiation has occurred, although few prospective studies have been performed in this field.
Keywords: Adjuvant chemotherapy, hormonal therapy, endometrial cancer, prognostic factors, radiation therapy.
Anti-Cancer Agents in Medicinal Chemistry
Title:Multidisciplinary Treatment of Early Stage Endometrial Cancer
Volume: 13 Issue: 6
Author(s): S. C. Cecere, C. Pisano, A. Bamias, M. Di Napoli, S. Rossetti, G. Facchini, R. Tambaro and S. Pignata
Affiliation:
Keywords: Adjuvant chemotherapy, hormonal therapy, endometrial cancer, prognostic factors, radiation therapy.
Abstract: Endometrial cancer is a highly curable malignancy when it presents as uterine-confined disease, but the prognosis for metastatic or recurrent endometrial cancer is poor. For those patients which are diagnosed at an early stage, surgery alone may be adequate for cure and clinical outcome is often favorable, with approximately 80 % of cases surviving at 5 years. However, after primary diagnosis and treatment, roughly 20-30% of patients are expected to recur within the following 5 years. Adjuvant treatment for endometrial cancer is not yet clearly defined. FIGO Stage I-III endometrial cancer patients, usually undergo surgery and some of them are offered adjuvant treatment based on risk assessment. Grade, age, stage are considered all independent risk factors for recurrence. Radiotherapy (RT) has been considered the adjuvant treatment of choice for decades, being able to reduce local recurrence rate and improving progression free survival, but without any impact on overall survival. In the last two decades, a shift toward the use of systemic chemotherapy (CT) in addition or instead of radiation has occurred, although few prospective studies have been performed in this field.
Export Options
About this article
Cite this article as:
Cecere C. S., Pisano C., Bamias A., Napoli Di M., Rossetti S., Facchini G., Tambaro R. and Pignata S., Multidisciplinary Treatment of Early Stage Endometrial Cancer, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (6) . https://dx.doi.org/10.2174/18715206113139990111
DOI https://dx.doi.org/10.2174/18715206113139990111 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recognition of Nucleic Acids by Toll-Like Receptors and Development of Immunomodulatory Drugs
Current Medicinal Chemistry Mast Cells and Basophils: Trojan Horses of Conventional Lin- Stem/Progenitor Cell Isolates
Current Pharmaceutical Design Novel Patents and Cancer Therapies for Transforming Growth Factor- Beta and Urokinase Type Plasminogen Activator: Potential Use of Their Interplay in Tumorigenesis
Recent Patents on Anti-Cancer Drug Discovery Talazoparib Loaded Solid Lipid Nanoparticles: Preparation, Characterization and Evaluation of the Therapeutic Efficacy In vitro
Current Drug Delivery Structure-Based Approach for the Discovery of Novel Selective Estrogen Receptor Modulators
Current Medicinal Chemistry Soy and Its Isoflavones: The Truth Behind the Science in Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Phytoestrogens in Postmenopause: The State of the Art from a Chemical, Pharmacological and Regulatory Perspective
Current Medicinal Chemistry A Review: The Anti-inflammatory, Anticancer and Antibacterial Properties of Four Kinds of Licorice Flavonoids Isolated from Licorice
Current Medicinal Chemistry Perspectives On Membrane-associated Progesterone Receptors As Prospective Therapeutic Targets
Current Drug Targets Indoleamine 2,3-Dioxygenase, an Emerging Target for Anti-Cancer Therapy
Current Cancer Drug Targets Redox Signaling Pathways Involved in Neuronal Ischemic Preconditioning
Current Neuropharmacology A Review on the Molecular Mechanisms Involved in the Placental Barrier for Drugs
Current Drug Delivery Activin Receptor-Like Kinases: Structure, Function and Clinical Implications
Endocrine, Metabolic & Immune Disorders - Drug Targets Premature Ageing Prevention: Limitations and Perspectives of Pharmacological Interventions
Current Drug Targets Mitochondrial Drug Targets in Cell Death and Cancer
Current Pharmaceutical Design Transcriptional Regulation as a Pharmacologic Intervention
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Steroidal Cardiac Na<sup>+</sup>/K<sup>+</sup> ATPase Inhibitors Exhibit Strong Anti-Cancer Potential <i>in vitro</i> and in Prostate and Lung Cancer Xenografts <i>in vivo</i>
Anti-Cancer Agents in Medicinal Chemistry A Review of Aberrant DNA Methylation and Epigenetic Agents Targeting DNA Methyltransferases in Endometriosis
Current Drug Targets Updates on the Role of FDG-PET/CT in Gynecological Malignancies
Current Molecular Imaging (Discontinued) Surgical Strategies for Fertility Preservation in Women with Cancer
Current Women`s Health Reviews